Table of Contents

Trulicity (dulaglutide) is a GLP-1 receptor agonist used to help manage type 2 diabetes in patients aged 10 and older. It improves blood sugar control and reduces the risk of major cardiovascular events in adults with established heart disease.

This medication is given as an injection and comes in various doses, which are gradually increased for the best results. Following the correct dosing and administration schedule is essential for its effectiveness.

In this article, we’ll break down the Trulicity dosing schedule and share important guidelines to ensure patients get the most benefit from their treatment.

Key Takeaways

  • Trulicity’s dosing schedule starts with 0.75 mg and can increase to 4.5 mg over 13 weeks for optimal blood sugar control.
  • Research shows Trulicity at 1.5 mg lowers blood sugar levels by 1.5% over 26 weeks.
  • Common side effects like nausea and vomiting are more frequent at higher doses (3 mg and 4.5 mg), but they are typically manageable and lessen over time.
  • The medication can be injected in the abdomen, thigh, or upper arm. It’s important to rotate the injection site with each dose to avoid irritation.
  • Regular blood sugar monitoring is essential, especially when increasing the dose, to ensure optimal effectiveness and adjust the treatment as needed.

Trulicity Dosage Forms

Here are the Trulicity dosage forms and strengths:

    • 0.75 mg/0.5 mL solution in a single-dose pen
    • 1.5 mg/0.5 mL solution in a single-dose pen
    • 3 mg/0.5 mL solution in a single-dose pen
    • 4.5 mg/0.5 mL solution in a single-dose pen
Trulicity 3mg Dosages

Trulicity Dosage Chart

The Trulicity weekly dose can be adjusted every 4 weeks based on individual needs. Below is the Trulicity dosing chart:

Week Dose
Week 1 0.75 mg once weekly
Week 5 1.5 mg once weekly (if additional control is needed)
Week 9 3 mg once weekly (if additional control is needed)
Week 13 4.5 mg once weekly (maximum dosage)

Trulicity Dosing Guide

The dosage increases gradually to help manage potential side effects. Below is the Trulicity dosing guide for further reference:

Week 1: Starting with 0.75 mg 

The Trulicity starting dose is at 0.75 mg. The patient’s blood sugar levels will be monitored regularly as per the healthcare provider’s advice. Trulicity at 0.75 mg reduces glucagon secretion and stimulates glucose-dependent insulin release.

In a Phase 3 monotherapy study, patients treated with this dosage experienced a 35.38 pmol/L increase in fasting insulin and a 0.09 nmol/L rise in C-peptide levels after 26 weeks.

Also, fasting glucagon levels decreased by 1.71 pmol/L from baseline, highlighting its effectiveness in improving insulin production and reducing glucagon for better blood sugar control.

Week 5: Increasing to 1.5 mg

After 4 weeks of monitoring the patient’s blood sugar levels, the dose can be increased to 1.5 mg if it still needs to be lowered. Research shows that treatment with Trulicity at 1.5 mg once weekly significantly improved blood sugar control. It reduced HbA1c levels by 1.5% over 26 weeks, outperforming placebo (0.5%) and exenatide (1.0%).

In a 52-week study, only 3.2% of patients on Trulicity at 1.5 mg (combined with metformin and pioglitazone) needed additional glycemic rescue, compared to 8.9% in the 0.75 mg group and 8.7% in the exenatide group. This shows that 1.5 mg of Trulicity is highly effective in lowering HbA1c and controlling blood sugar.

Week 9: Moving up to 3 mg

If the patient still needs to lower their blood sugar levels, the Trulicity dose can be increased to 3 mg after four weeks to manage the side effects. A study on Trulicity in 1,842 patients with type 2 diabetes found that the 3 mg dose reduced HbA1c more effectively than the 1.5 mg dose when using one measurement method.

Side effects, including nausea (15.6%) and vomiting (8.3%), were slightly more common with the 3 mg dose than the 1.5 mg dose but occurred less frequently than with the 4.5 mg dose.

Week 13: Maximum dose at 4.5 mg

After 4 weeks, if the patient still needs to decrease the blood sugar levels, they can be given the maximum dosage of Trulicity at 4.5 mg. A clinical trial involving 1,842 people with type 2 diabetes showed that higher doses of Trulicity led to better outcomes.

After 36 weeks, the 4.5 mg dose significantly reduced HbA1c levels compared to the 1.5 mg dose. The 4.5 mg dose was more effective for weight loss than 1.5 mg. Common side effects, including nausea and vomiting, occurred slightly more frequently at higher doses.

Additional Trulicity Dosing Instructions

1. Learn Proper Injection Technique

    • Ensure the patient is trained on the correct way to inject before starting.

2. Injection Timing

    • Inject once a week, at any time of day, with or without food.

3. Choose Injection Site

    • Inject in the abdomen, thigh, or upper arm.
    • Rotate the injection site with each dose.

4. Inspect the Medication

    • Check the medication if it is clear and colorless.
    • Do not use it if it is cloudy or discolored.

5. Combining with Insulin

    • Do not mix Trulicity and insulin in the same syringe.
    • Both can be injected in the same body region, but make sure they are not injected too close to each other.

Trulicity Missed Dose Guidelines

    • If a dose is missed, it should be taken as soon as possible if the next dose is more than 3 days (72 hours) away.
    • If less than 3 days remain until the next dose, the missed dose should be skipped, and the regular dosing schedule should be followed.
    • The day of the weekly dose can be changed if the last dose was taken 3 or more days earlier.

Final Insights

Trulicity offers a flexible and effective dosing schedule to manage type 2 diabetes, with dosage options ranging from 0.75 mg to 4.5 mg. The medication has demonstrated consistent efficacy in reducing blood sugar levels with higher doses, leading to more significant improvements in blood sugar and weight loss than lower doses.

While common side effects such as nausea and vomiting may increase with higher doses, they remain manageable. Trulicity’s flexible dosing, careful monitoring, and adherence to guidelines can help patients effectively manage their blood sugar levels. Always consult a healthcare provider for Trulicity dosing concerns.

Frequently Asked Questions

Trulicity side effects, such as nausea, typically last for the first 2 to 3 days after the initial dose. For most people, nausea subsides within the first two weeks of treatment. However, some individuals may continue to experience nausea beyond the second week. Less than 2% of users had to discontinue Trulicity due to nausea.

The list price of Trulicity is $977.42 per month, but the cost a patient pays will depend on their insurance plan. Alternatively, Trulicity can be purchased from online platforms such as Pharma Giant for a reduced price of $282.

Trulicity stays in the system for about 25 days after the last dose. This is because its half-life is approximately 5 days, meaning it takes around 5 half-lives for the body to eliminate the drug.

Trulicity and Ozempic are not the same. Both are GLP-1 receptor agonists used to treat type 2 diabetes, but Trulicity contains dulaglutide while Ozempic contains semaglutide. They also have distinct dosing regimens.

Taking a double dose of Trulicity may increase the risk of side effects such as nausea or vomiting. If this happens, a patient should contact the doctor immediately or proceed to the nearest emergency room immediately.

Studies show that Trulicity begins to reduce glucose levels within 24 hours of the first injection, with effects maintained for at least a week. It is effective regardless of factors such as age, BMI, or previous diabetes treatments.

Trulicity can be stored in the refrigerator for up to 14 days at temperatures between 36°F and 46°F (2°C to 8°C). Keep the medicine at room temperature up to 86°F or 30°C for 14 days. It should not be frozen, and should not be used if frozen.

Trulicity is intended for long-term use. Patients can take it for several years. However, the duration of treatment should be determined in consultation with a healthcare provider, who will monitor progress and make adjustments as needed.

Related Articles

Sources

American Heart Association. (2024). Diabetes 2024 statistics infographic. https://newsroom.heart.org/file/diabetes-2024-statistics-infographic?action=

Marathe, P. H., Gao, H., Close, K. L., & American Diabetes Association. (2016). Comprehensive review of diabetes management: Role of GLP-1 receptor agonists. PMC4894510. https://pmc.ncbi.nlm.nih.gov/articles/PMC4894510/

Eli Lilly and Company. (2023). Trulicity® (dulaglutide) injection, for subcutaneous use: Prescribing information. https://pi.lilly.com/us/trulicity-uspi.pdf

U.S. Food and Drug Administration. (2020). Trulicity (dulaglutide) injection, for subcutaneous use: FDA label information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125469s036lbl.pdf

Htel, T. L., Nordgren, M., & Golan, R. A. (2021). Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg vs. 1.5 mg in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Care, 44(3), 765-775. https://doi.org/10.2337/dc20-1352

Eli Lilly and Company. (n.d.). Trulicity: How to use and potential side effects. https://trulicity.lilly.com/how-to-use/side-effects

Eli Lilly and Company. (n.d.). Trulicity pricing information. https://pricinginfo.lilly.com/trulicity

McCarthy, C. (2023). Trulicity (dulaglutide): How it works, side effects, and more. Healthline. https://www.healthline.com/health/drugs/trulicity#how-it-works

Eli Lilly and Company. (n.d.). Ozempic prescribing information. https://www.ozempic.com/prescribing-information.html

Lee, Y., Lee, H., & Kim, H. (2021). The safety and efficacy of GLP-1 receptor agonists, including dulaglutide, in diabetes management: A systematic review. PMC8519979. https://pmc.ncbi.nlm.nih.gov/articles/PMC8519979/